New drugs in prostate cancer

Sangjun Yoo, Se Young Choi, Dalsan You, Choung Soo Kim

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other treatments are slim, and the need for new agents persists. In recent years, novel agents, including abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, have been approved for the treatment of CRPC, and more such agents based on diverse mechanisms are under investigation or evaluation. In this article, the authors reviewed the current literature on recent advances in medical treatment of prostate cancer, especially CRPC. In addition, the authors elaborated on novel drugs for prostate cancer currently undergoing investigation and their mechanisms.

Original languageEnglish
Pages (from-to)37-42
Number of pages6
JournalProstate International
Issue number2
StatePublished - Jun 2016


  • Castration Resistant
  • Drug Therapy
  • Drugs
  • Investigational
  • Prostatic Neoplasm


Dive into the research topics of 'New drugs in prostate cancer'. Together they form a unique fingerprint.

Cite this